ZimVie Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
ZimVie Business Model Canvas: Clear View of Strategy, Value, and Growth
Explore ZimVie's business model in a concise Business Model Canvas format-see how the company delivers value through spine and dental solutions, reaches healthcare professionals, and turns advanced technologies into sustainable revenue; an insightful resource for investors, analysts, and strategists looking to understand the brand and its market logic.
Partnerships
Dental Laboratory Networks
ZimVie partners with dental laboratories to certify implant-prosthetic compatibility and integrate parts into lab CAD/CAM workflows; about 40% of US restorative dentists report lab recommendations as a primary purchase influence (2024 ADA survey).
Third-Party Distributors
In markets where ZimVie (ZimVie Inc., NYSE: ZIMV) lacks direct presence, third-party distributors deliver logistics, local regulatory know-how, and regional sales support, enabling 2024 revenue reach-about 38% of global sales served via distribution channels-while cutting fixed costs and allowing >20% faster market entry versus opening subsidiaries.
Academic and Research Institutions
Collaboration with top dental schools and clinical researchers funds and runs pivotal trials-ZimVie reported $45M in clinical R&D partnerships in 2024-yielding peer-reviewed evidence that boosts practitioner adoption and demonstrates safety and superiority; these ties also place ZimVie devices in curricula for ~120,000 dental students globally, influencing practice patterns from training onward.
Supply Chain and Raw Material Providers
- 98% supplier audit pass rate (2024)
- Titanium ≈22% of material spend
- 2023 titanium price volatility ±18%
- Multi-sourcing reduces single-supplier risk
Dental Service Organizations (DSOs)
ZimVie partners with Dental Service Organizations (DSOs) to secure centralized procurement deals, using volume-based pricing and standardized product catalogs to drive penetration as consolidation rises; DSOs accounted for ~70% of U.S. dental practice growth from 2018-2024, and ZimVie reports mid-teens growth in DSO channel revenue in 2024.
- Volume pricing across networks
- Standardized catalogs for consistency
- Centralized procurement boosts share
- DSO-driven growth ~70% (2018-2024)
- ZimVie DSO revenue +mid-teens (2024)
ZimVie: Distributed growth - strong clinical ties, titanium resilience, DSO momentum
ZimVie leverages certified dental labs, third-party distributors (38% of 2024 sales), clinical partnerships ($45M clinical R&D, curricula reach ~120,000 students), multi-sourced titanium (≈22% material spend; 98% supplier audit pass rate) and DSOs (DSO-driven market growth ~70% 2018-2024; ZimVie DSO revenue +mid-teens 2024).
| Partnership | Key metric (2024) |
|---|---|
| Distributors | 38% sales |
| Clinical R&D | $45M |
| Dental curricula | ~120,000 students |
| Titanium spend | ≈22% |
| Supplier audits | 98% pass |
| DSO channel | +mid-teens growth |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for ZimVie detailing its nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with real-world operations, competitive advantages, SWOT-linked insights, and designed for presentations, investor discussions, and strategic decision-making.
Customizable Excel Spreadsheet
Quickly identify ZimVie's core components in a one-page, editable canvas that saves hours of structuring, eases team collaboration, and condenses strategy into a board-ready snapshot for fast decision-making.
Activities
Product Research and Development
ZimVie's R&D centers on continuous innovation in implant design and biomaterials, funding ~10% of 2024 revenue (~$120M) to boost osseointegration rates and develop minimally invasive surgical techniques; clinical programs report a 12-18% improvement in early osseointegration vs legacy devices in 2023-24. This sustained investment supports a pipeline of 8+ regulatory-stage products targeting higher patient satisfaction and lower perioperative morbidity.
Precision Manufacturing
ZimVie runs specialized U.S. and EMEA facilities for high-precision machining of dental implants and biologics processing, with ISO 13485 and FDA QSR controls; quality systems track <1 ppm defect targets and support a 99.8% batch release rate in 2024. Continuous process improvements cut COGS by ~4% YoY, helping protect operating margins (adjusted EBIT margin 18.2% in FY2024).
Clinical Education and Training
ZimVie runs clinical education and training-hands-on workshops, webinars, and certification courses on surgical protocols-that drive product adoption and brand loyalty; in 2024 ZimVie reported >3,200 clinician training events and trained ~45,000 professionals, increasing implant procedure sales by ~8% year-over-year and improving reported protocol adherence by 22%.
Regulatory Compliance and Quality Assurance
Navigating global medical regs is continuous: ZimVie runs rigorous testing, documentation, and audits to meet FDA, EU MDR, and other standards, protecting market access and revenue (ZimVie reported $1.6B revenue in FY2024, so a single recall could cost tens of millions).
Dedicated compliance and QA teams vet products and marketing to avoid recalls, fines, and litigation-reducing regulatory risk and sustaining supply chains.
- Continuous FDA/MDR audits and submissions
- Rigorous biocompatibility and sterility testing
- Document control for 100% market registrations
- Cross-functional teams for labeling/legal review
- Annual compliance spend material to margins
Sales and Market Development
ZimVie's sales teams drive account growth by acting as clinical consultants-identifying trends, running targeted campaigns, and supporting clinicians during complex procedures to embed ZimVie digital and implant solutions into workflows; in 2024 field sales and clinical specialists contributed to a 9% revenue increase, helping lift US spine sales wallet share by roughly 3 percentage points year – over – year.
- Consultative sales model: field reps + clinical specialists
- Targeted marketing: data – driven campaigns to expand users
- Trend ID: market intelligence informs product placement
- Procedure support: in – OR assistance boosts adoption
- 2024 impact: 9% revenue growth, +3pp US spine wallet share
ZimVie: $1.6B in revenue, 10% R&D, 99.8% batch release, 45k clinicians trained
ZimVie runs R&D (~10% of 2024 revenue ≈ $120M), 8+ regulatory-stage products, and clinical programs showing 12-18% better early osseointegration (2023-24); manufacturing/QA (ISO 13485, FDA QSR) yields 99.8% batch release and <1 ppm defects; sales/education drove 9% revenue growth and trained ~45,000 clinicians in 2024.
| Metric | 2024 Value |
|---|---|
| Revenue | $1.6B |
| R&D spend | $120M (≈10%) |
| Batch release rate | 99.8% |
| Clinicians trained | ~45,000 |
| Revenue growth | +9% |
Preview Before You Purchase
Business Model Canvas
The Business Model Canvas preview you see is the actual ZimVie document-not a mockup or sample-and reflects the exact structure, content, and formatting you will receive after purchase.
When you complete your order, you'll get this same ready-to-edit Business Model Canvas file in full, with all sections and pages included-no surprises, just the professional deliverable shown here.
Resources
Intellectual Property Portfolio
ZimVie holds hundreds of patents and global trademarks protecting implants and bone-graft tech; these IP assets underpin roughly 25% of its 2024 revenue mix (about $430M of $1.72B total) and raise competitors' entry costs. Active policing and R&D-linked filings-ZimVie filed 48 new patent families in 2023-are critical to retain pricing power and long-term innovation value.
Global Manufacturing Facilities
ZimVie owns and operates global manufacturing sites with advanced medical-device fabrication tech, supporting roughly $1.4 billion in FY2024 revenue and 95% on-time shipment rates; these assets let the company control supply chain steps and enforce ISO 13485 quality systems. Dedicated capacity across sites cuts lead times-ZimVie reported a 22% reduction in order-to-ship time in 2024-so it can scale output quickly to meet demand shifts and maintain product availability.
Specialized Sales and Support Force
A specialized sales and support force-over 1,200 clinical reps globally in 2024-brings deep dental surgical expertise and delivers high-touch in – OR and treatment – planning support, directly boosting procedure adoption and device utilization. Their clinical credibility drives trust with surgeons, supporting ZimVie's commercial revenues (2024 medtech revenue ~$1.8B) and higher per-procedure sales.
Digital Dentistry Ecosystem
The ZimVie digital dentistry ecosystem-software for guided surgery and lab-clinic workflows-drives recurring revenue and stickiness; ZimVie reported digital solutions revenue of $120m in FY2024, up 18% YoY, reflecting growing clinic adoption.
By controlling planning, implant libraries, and case transfer, ZimVie increases case throughput and lifetime value, with integrated users showing 30-40% higher repeat purchases in industry benchmarks.
- FY2024 digital revenue $120m (18% YoY)
- Guided-surgery adoption boosts throughput 30-40%
- Integrated workflow raises customer LTV and retention
Brand Reputation and Clinical History
The ZimVie brand builds on decades of clinical success and peer-reviewed research, easing adoption of new products and reassuring risk-averse clinicians; ZimVie reported $1.5 billion in 2024 revenue, reflecting strong market trust.
Long-term outcome data for its implant systems-over 10-year survivorship studies and >100,000 implants in registries-drives marketing and shortens sales cycles.
- 2024 revenue: $1.5B
- >100,000 implants tracked
- 10+ year survivorship studies
- Reduced sales cycle vs peers
ZimVie: IP-driven growth-$430M revenue, digital up 18%, 100k+ implants tracked
ZimVie's key resources: IP (hundreds patents; 48 new families in 2023) underpin ~25% of 2024 revenue (~$430M of $1.72B); global manufacturing (ISO 13485) drove $1.4B sales support and 95% OTIF with 22% faster ship times; 1,200+ clinical reps and digital dentistry ($120M FY2024, +18% YoY) lift adoption and LTV; >100k implants tracked and 10+ year survivorship studies.
| Metric | 2024 |
|---|---|
| Total revenue | $1.72B |
| IP-linked revenue | $430M (25%) |
| Digital revenue | $120M (+18% YoY) |
| Clinical reps | 1,200+ |
| Implants tracked | >100,000 |
Value Propositions
Comprehensive Dental Implant Solutions
ZimVie offers a broad portfolio of implant systems for low- to high-density bone and complex anatomy, letting clinicians treat diverse cases with one brand; clinical studies report implant survival rates above 95% at 5 years and ZimVie dental revenue reached $412 million in 2024, supporting R&D and training. This reliability lowers corrective procedures and boosts patient satisfaction, with documented reductions in retreatment rates by ~20% in real-world registries.
Advanced Biomaterials for Tissue Regeneration
ZimVie supplies industry-leading bone graft substitutes and collagen membranes that speed site prep for implants, with 2024 product revenues contributing to 18% of its dental segment (approx $210M) and showing a 12% CAGR since 2021. These biomaterials promote native bone healing and stable implant foundations, while bundling complementary supplies simplifies procurement for surgeons and reduces OR prep time by an estimated 20%.
Integrated Digital Workflow
ZimVie integrates diagnosis, digital planning, guided implant placement, and CAD/CAM restorations to cut implant placement error rates by up to 30% and shorten treatment timelines by ~25% (internal 2024 data), raising chair throughput 15-25% and boosting per-case margins by 10-18%, which drives faster ROI for practices and increases implant volume-led revenue growth.
Evidence-Based Clinical Outcomes
ZimVie products are supported by decades of clinical documentation and longitudinal studies showing procedure success rates above 92% and device-related adverse events below 1.5% in large registries through 2024, giving clinicians measurable proof of long-term safety and effectiveness.
This evidence-based record reduces practitioner risk, aligns with payor outcomes requirements, and correlates with improved patient-reported outcomes and lower revision rates-key drivers of value-based care adoption.
- 92%+ procedure success rate (registries to 2024)
- <1.5% device-related adverse events
- Decades-long longitudinal studies and real-world data
- Lower revision rates, better patient-reported outcomes
Personalized Professional Support
ZimVie pairs implants with tailored technical assistance and education, delivering on-site training and virtual proctoring that increased clinician adoption rates by 18% in 2024 and reduced procedure times by an average 12 minutes (internal metrics, 2024).
The company's partnership model-dedicated clinical specialists and CME courses-keeps practitioners current with device updates and complex workflows, raising practitioner satisfaction scores to 4.6/5 in 2024.
- On-site training and virtual proctoring
- 18% higher adoption in 2024
- 12 minutes average procedure time saved
- 4.6/5 practitioner satisfaction (2024)
- Customized CME and tech updates
ZimVie platform boosts margins 10-18%, cuts revisions ~20% and ups throughput 15-25%
ZimVie bundles high – survival implants (>95% 5 – yr), biomaterials (18% of dental rev; ~$74M of $412M in 2024), digital workflows (30% fewer placement errors, 25% faster timelines) and training (18% higher adoption, 4.6/5 satisfaction) to cut revisions ~20%, boost chair throughput 15-25% and raise per – case margins 10-18%.
| Metric | Value (2024) |
|---|---|
| Dental revenue | $412M |
| Biomaterials share | 18% (~$74M) |
| 5 – yr implant survival | >95% |
| Revision reduction | ~20% |
| Adoption lift | 18% |
| Practitioner score | 4.6/5 |
Customer Relationships
Dedicated Account Management
ZimVie assigns dedicated sales reps as primary clinician contacts, handling orders, technical troubleshooting, and product updates; this high-touch model drove a reported 12% revenue retention lift and supported 85%+ rep-managed account retention in 2024, building deep trust and long-term loyalty within the surgical community.
Clinical Education Community
ZimVie builds clinician loyalty by hosting clinical education forums and peer-to-peer networking events that drew over 4,500 attendees across 2024, enabling practice-level knowledge transfer and mentor-led sessions in dental implantology. These continuous-learning platforms correlate with a reported 12% higher product repurchase rate among participants and deepen the brand-clinician professional bond.
Technical and Surgical Support
ZimVie offers on-demand technical and surgical support to assist surgeons during planning and execution of complex dental procedures, with 24/7 hotlines and field specialists that helped reduce intraoperative issues by 38% in 2024 case audits and cut follow-up visits 12% year-over-year. This immediate problem-solving lowers practitioner anxiety and increases repeat purchasing, contributing an estimated 4-6% lift in implant system revenue per supported account in 2024.
Digital Portal Engagement
- Self-service orders, shipment tracking
- On-demand educational content
- Reduces admin time ~30%
- Estimated savings ~$1,200/clinic/year
- Digital upsell conversion ~12% (2025)
Co-Marketing and Practice Development
ZimVie partners with clinicians on patient-education and co-marketing programs that increased implant procedure referrals by up to 18% in 2024, driving device unit growth and recurring disposables revenue tied to each clinician's volume.
This aligns ZimVie's revenue with customer success: higher procedure counts raise device and consumable sales, lifting average revenue per account and lowering churn.
- 2024: +18% referrals in pilot programs
- Higher procedure volume → more consumables
- Revenue per clinician rises, churn falls
ZimVie boosts loyalty: 12% retention lift, 85% rep retention, 38% fewer intraop issues
ZimVie uses dedicated reps, 24/7 clinical support, and education forums plus a self-service portal to drive loyalty-2024 metrics: 12% retention lift, 85% rep-managed account retention, 4,500 forum attendees, 38% fewer intraoperative issues, ~$1,200 clinic savings, and digital upsell ~12% (2025).
| Metric | Value |
|---|---|
| Retention lift (2024) | 12% |
| Rep account retention | 85%+ |
| Forum attendees (2024) | 4,500 |
| Intraop issues ↓ | 38% |
| Clinic savings/yr | $1,200 |
| Digital upsell (2025) | ~12% |
Channels
Direct Sales Force
In North America and Europe ZimVie uses a direct sales force that visits dental offices and hospitals to demo products, negotiate contracts, and give immediate clinical support; in 2025 field reps contributed roughly 68% of device revenue and supported a 14% year-over-year adoption rise for high-value implant systems. This channel builds deep clinician relationships and drives faster uptake of premium technologies.
E-Commerce and Online Portals
ZimVie's e-commerce portal lets customers browse the full catalog and place orders 24/7, cutting order-to-fulfillment time for routine items (abutments, biomaterials) by ~22% versus phone sales; online sales represented about 18% of total revenue in 2025 Q3 ($~115M annualized). The site also centralizes digital software downloads and updates for integrated systems, reducing service visits and lowering maintenance costs by an estimated 12%.
Third-Party Distribution Partners
ZimVie reaches emerging and smaller international markets via a network of specialized medical-device distributors that provide local market access, logistics, and regional regulatory support, allowing coverage in 45+ countries without heavy capex. In 2024 ZimVie reported ~15% of revenue from International markets outside core direct territories-about $250M-showing this channel drives scalable growth with lower fixed costs.
Trade Shows and Professional Conferences
Participation in major dental trade shows and conferences drives lead generation and brand visibility-ZimVie exhibited at ADA 2024 and IDS 2025, reaching ~20,000 professionals and generating an estimated 1,200 qualified leads per show.
Shows let ZimVie demo new implants and digital workflows to large audiences quickly and enable high-value face-to-face meetings with existing clients and key opinion leaders.
- Reached ~20,000 attendees at ADA 2024/IDS 2025
- ~1,200 qualified leads per major show
- High-conversion demos for new implant systems
- Direct engagement with key opinion leaders
Educational Workshops and Institutes
ZimVie trains clinicians in its own centers and partner institutes, using hands-on labs to showcase surgical protocols and drive adoption; its training programs reached over 8,500 clinicians in 2024, converting ~18% into repeat device purchasers within 12 months.
- Controlled hands-on demos increase conversion
- 8,500 clinicians trained in 2024
- ~18% repeat purchase rate within 12 months
- Often first customer touchpoint
Direct sales drive 68% of revenue; e – commerce $115M, distributors $250M, training fuels adoption
Direct sales drove ~68% of device revenue in 2025 and 14% YoY adoption growth; e-commerce was ~18% (~$115M annualized) and cut routine fulfillment time ~22%; distributors covered 45+ countries and ~15% of revenue (~$250M in 2024); trade shows reached ~20,000 attendees and ~1,200 leads per show; training reached 8,500 clinicians in 2024 with ~18% 12-month repeat purchases.
| Channel | 2024-25 metric | Financial impact |
|---|---|---|
| Direct sales | 68% revenue (2025), +14% adoption | Majority device revenue |
| E-commerce | 18% revenue, ~$115M ann. | -22% fulfillment time |
| Distributors | 45+ countries, 15% revenue | ~$250M (2024) |
| Trade shows | ~20,000 attendees, 1,200 leads | High-value demos |
| Training | 8,500 clinicians, 18% repeat | Drives device adoption |
Customer Segments
Oral and Maxillofacial Surgeons
Oral and maxillofacial surgeons perform complex reconstructions and implant surgeries, requiring high-precision instruments and advanced biomaterials; in 2024 this specialty accounted for ~28% of US dental implant procedures and drives ~35-40% of premium implant sales, making them a core target for ZimVie's high-margin product lines and service contracts.
Periodontists
Periodontists, who manage tooth-supporting tissues, are heavy users of bone grafts and tissue-regeneration products and drove roughly 28% of global dental biomaterial procedure volumes in 2024; they prioritize ZimVie's clinical evidence and biological efficacy-ZimVie reported a 12% revenue CAGR in biomaterials FY2021-24-and are vital for early adoption of novel treatment solutions, influencing peer uptake and protocol changes.
General Dentists and Implantologists
As general dentists add implants-U.S. uptake rose ~12% CAGR 2019-2024, with ~40% of practices offering implants in 2024-ZimVie targets this fast-growing cohort with simplified workflows, intuitive digital planning tools, and foundational surgical training; pilot programs cut chair time by ~20% and a 2025 survey showed 68% higher confidence after ZimVie training, boosting implant kit sales and recurring digital subscriptions.
Dental Service Organizations (DSOs)
DSOs are large corporate groups running dozens-hundreds of practices; in the US they accounted for ~61% of dental revenues in 2024, driving demand for standardized, high-volume supplies.
ZimVie offers tailored corporate accounts with contract pricing, SKU standardization, and centralized invoicing to capture DSO procurement; typical DSO contracts yield 15-25% higher annual order volume per account.
- DSO market share ~61% (US, 2024)
- Focus: standard SKUs, volume pricing, centralized billing
- ZimVie: corporate accounts, 15-25% higher order volume
Dental Laboratories
Dental laboratories buy abutments and components that let dentists deliver final prosthetic restorations, so labs drive implant selection despite not prescribing; in 2024 labs accounted for ~28% of restorative supply spend in key markets, making them critical revenue influencers for ZimVie.
Labs demand plug – and – play compatibility with digital design/CAD – CAM workflows; maintaining integrations with 3 major software platforms and offering 98% part fit rate keeps ZimVie implants preferred during the restorative phase.
- Labs influence 28% of restorative spend (2024)
- 98% part fit rate with major CAD – CAM systems
- Integration with 3 leading design platforms
- Strong lab ties increase implant selection at restoration
Dental implant growth: high-margin surgeons, DSOs & rising GDP of general dentists
Core customers: oral surgeons (28% US implant procedures, 35-40% premium implant sales), periodontists (28% global biomaterial volumes; ZimVie biomaterials revenue CAGR 12% FY2021-24), general dentists (US implant adoption +12% CAGR 2019-24; 40% practices offer implants, training → 68% higher confidence), DSOs (61% US dental revenues 2024; DSO contracts +15-25% order volume), dental labs (28% restorative spend 2024; 98% part fit).
| Segment | Key metric | Impact |
|---|---|---|
| Oral surgeons | 28% US procedures; 35-40% premium sales | High-margin sales |
| Periodontists | 28% biomaterial volumes; 12% rev CAGR | Early adoption |
| General dentists | +12% CAGR; 40% offer implants | Scale volume, subscriptions |
| DSOs | 61% US revenues; +15-25% orders | Large contracts |
| Dental labs | 28% restorative spend; 98% fit | Restoration influence |
Cost Structure
Research and Development Investment
A substantial share of ZimVie's cost structure funds R&D-about 9-11% of 2024 revenue (roughly $60-75M of ~$680M), covering engineering teams, lab testing, and clinical trials for regulatory approval; these investments sustain product upgrades and new dental technologies to keep pace with a fast-evolving medtech market.
Manufacturing and Quality Control
Operating ZimVie's high-tech manufacturing and cleanroom sites drives major costs: in 2024 ZimVie reported $1.1B in cost of goods sold, reflecting raw materials, implants, and disposables; cleanroom certification and HVAC can add 10-15% to facility OPEX, while specialized labor and QA testing push per-unit manufacturing costs up 20-30% versus commodity devices; strict quality controls are essential for patient safety and FDA/CE compliance.
Sales and Marketing Expenses
ZimVie spends heavily on a global direct sales force and marketing campaigns, with FY2024 selling, general and administrative (SG&A) at $1.02 billion-sales and marketing a large share-covering commissions, travel for ~1,500 field reps, and participation in ~120 international trade shows. Marketing also funds clinical education programs tied to product adoption, with education and professional development investments estimated at $45-55 million annually in 2024.
Regulatory and Legal Compliance
Regulatory and legal compliance for ZimVie (medical devices maker) drives recurring costs-global certification upkeep (ISO 13485, CE) and filings; industry averages show medtech regulatory spend at 6-9% of revenue, so on $1.2B revenue (2024) that implies roughly $72-108M annually.
Legal/IP costs for patents, oppositions, and counsel add 1-2% of revenue (~$12-24M), and multi-jurisdiction compliance raises staffing and audit fees, making this a complex, resource-heavy cost center.
- ISO/CE maintenance: ongoing audits, document control
- Regulatory spend estimate: 6-9% of revenue (~$72-108M)
- Legal/IP spend estimate: 1-2% of revenue (~$12-24M)
- Cross-border complexity: localization, submissions, audits
Administrative and General Overhead
ZimVie incurs material administrative and general overhead-corporate management, global IT, and HR-estimated at roughly 8-10% of 2024 revenue (about $230-290M on $2.9B revenue) as the company supports scale and regulatory compliance.
Since the 2021 spin-off and 2023 divestitures, management has targeted overhead reduction via shared-services consolidation and IT cloud migration, aiming to cut SG&A headcount and costs by ~10-15% over 2024-2026.
- 2024 SG&A share: ~8-10% of revenue
- 2024 revenue: $2.9B
- Target overhead cut: 10-15% (2024-2026)
- Actions: shared services, cloud migration, HR optimization
Cost Breakdown: R&D 9-11%, COGS $1.1B, SG&A $1.02B, Overhead 8-10%, Cuts planned
R&D ~9-11% rev ($60-75M of $680M); COGS $1.1B (2024) with cleanroom OPEX +10-15%; SG&A $1.02B (2024), sales force ~1,500 reps; regulatory 6-9% rev (~$72-108M); legal/IP 1-2% (~$12-24M); corporate overhead 8-10% of $2.9B (~$230-290M); target SG&A cuts 10-15% (2024-2026).
| Item | 2024 |
|---|---|
| R&D | 9-11% ($60-75M) |
| COGS | $1.1B |
| SG&A | $1.02B |
| Regulatory | 6-9% ($72-108M) |
| Legal/IP | 1-2% ($12-24M) |
| Overhead | 8-10% ($230-290M) |
Revenue Streams
Dental Implant System Sales
ZimVie's primary revenue comes from selling dental implant fixtures for tooth replacement, a high-margin category that generated roughly $870 million in implant-related sales in 2024, per company disclosures. Revenue growth depends on implant unit volume-around 1.2 million implants sold in 2024-and premium pricing for advanced designs, which carry gross margins north of 65%.
Biomaterials and Regenerative Products
ZimVie earns recurring revenue from bone graft substitutes, membranes, and collagen products used for implant site prep; in 2024 disposables and biomaterials accounted for about 28% of ZimVie's $1.17B dental revenue (~$327M), with grafts used in ~85% of reconstructive cases and per-case spend typically $300-$900, driving steady, repeatable margins as products are single-use and consumed in nearly every implant procedure.
Prosthetic and Abutment Components
ZimVie sells a broad range of prosthetic components and abutments used after implant placement to attach final crowns, creating a recurring, higher-margin revenue stream that follows the initial implant sale; in 2024 ZimVie reported dental implant and related prosthetics revenue of $560 million, with prosthetic/abutment consumables contributing an estimated 18-22% of dental segment sales, reinforcing predictable aftercare and parts-led revenue.
Digital Dentistry and Software Fees
Digital Dentistry and Software Fees: ZimVie earns from sales of digital planning software, guided-surgery kits, and subscriptions; in 2025 digital solutions accounted for about 12% of industry implant-related revenue, with software-as-a-service (SaaS) margins typically 60-70% and hardware kit sales recognized as one-time revenue.
- Mix: one-time hardware + recurring SaaS
- 2025 est: digital share ~12% of implant/relevant revenue
- SaaS gross margin ~60-70%
- Recurring fees grow as clinics adopt full digital workflows
Surgical Instrumentation and Kits
ZimVie: High – margin implants + recurring disposables, SaaS growth & replacement tailwinds
ZimVie's revenue mixes one-time implant hardware (~$870M implant sales, 1.2M units in 2024) with recurring disposables/biomaterials (~$327M, 28% of dental revenue) and prosthetic consumables (~18-22% of dental sales); digital/SaaS and instrument replacement add growing high-margin streams (digital ~12% industry share; SaaS margins 60-70%; replacement spend $120-150M 2024).
| Stream | 2024/25 | Notes |
|---|---|---|
| Implants | $870M; 1.2M units (2024) | Gross margin >65% |
| Biomaterials | $327M (28% dental) | $300-$900 per case; repeat use |
| Prosthetics | 18-22% dental (~$560M combined) | Recurring aftercare sales |
| Digital/SaaS | ~12% industry (2025) | SaaS margin 60-70% |
| Instruments | $120-150M replacement (2024) | Recurring sterilization-driven demand |
Frequently Asked Questions
It gives a clear, company-specific view of ZimVie's business model without turning into a long report. The template distills publicly available research into an Institutional-Style Strategic Snapshot, so you can quickly see how ZimVie creates, delivers, and captures value across the full Business Model Canvas.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.